Diuretics as First-Line Blood Pressure Treatment

Guideline-Based Recommendation

The European Society of Cardiology recommends diuretics as first-line treatment for hypertension, with thiazide-type diuretics being the preferred choice based on proven cardiovascular mortality and morbidity reduction 1, 2
The Joint National Committee and World Health Organization classify diuretics as the only first-choice drug for starting treatment in patients with hypertension 1

Chlorthalidone is the preferred thiazide diuretic based on its prolonged half-life and proven reduction of cardiovascular disease in clinical trials, such as ALLHAT and SHEP 3
Network meta-analyses demonstrate superior benefit of chlorthalidone over hydrochlorothiazide on clinical outcomes, including reduced stroke, heart failure, and cardiovascular disease events 3
The European Society of Hypertension/European Society of Cardiology guidelines note that claims of hydrochlorothiazide inferiority are confined to limited trials without head-to-head comparisons 1, 2

The American College of Cardiology recommends starting with chlorthalidone 12.5 mg once daily, with titration to 25 mg once daily if blood pressure target is not achieved within 2-4 weeks 3
If chlorthalidone is unavailable, hydrochlorothiazide 25 mg once daily may be used as an alternative, with option to increase to 50 mg daily 3

The European Society of Cardiology recommends monitoring serum potassium, sodium, creatinine, and eGFR within 2-4 weeks of initiation or dose escalation of chlorthalidone, due to the risk of hypokalemia and other electrolyte imbalances 3
Hypokalemia can contribute to ventricular ectopy and possible sudden death, making potassium monitoring critical, especially with chlorthalidone 3

The European Society of Cardiology notes that only low-dose thiazide diuretics and ACE inhibitors have been shown to reduce all-cause mortality in hypertensive patients compared with placebo 1, 2
Calcium antagonists may be slightly more effective in preventing stroke but are inferior to diuretics by approximately 20% in preventing new-onset heart failure 1, 2

In patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), chlorthalidone is specifically superior to hydrochlorothiazide, reducing 24-hour ambulatory BP by 10.5 mm Hg over 12 weeks 3
Diuretics should not be automatically discontinued when eGFR decreases to <30 mL/min/1.73 m², and may be beneficial in reducing cardiovascular events in diabetic patients 3